Hub ยท Peptide Science
Solid-phase peptide synthesis: principle, limits and quality testing
Solid-phase peptide synthesis (SPPS) builds a peptide chain one amino acid at a time while the growing chain stays covalently anchored to an insoluble polymer resin bead. Because the resin-bound chain is not purified between steps, crude products can carry deletion sequences, truncated chains and chemical modifications. Published guidance notes that verifying a purified synthetic peptide calls for independent analytical methods beyond a single HPLC check.
01How it worksContents
Picture threading beads onto a string whose far end is tied to a workbench. After each bead goes on, you can rinse away loose pieces without losing the string. Solid-phase peptide synthesis works on that idea, except the string is a growing chain of amino acids and the workbench is a tiny crosslinked polymer bead swollen with solvent.
This page is part of the peptide science hub. It summarises a 2025 perspective essay by Stephen Kent on how solid-phase synthesis works, why by-products build up during chain assembly, and what those limits mean for analytical testing. It is research reference material, for research use only. It gives no synthesis protocol and makes no claim about how any Form Laboratories product was made.
- Guidethe peptide science hubPeptide science questions answered from published studies and regulator records: what peptides are, which are approved in Australia and by the FDA, and where research peptides sit.
Key facts
| What SPPS is | Stepwise chemical assembly of a peptide chain covalently anchored to an insoluble resin support |
|---|---|
| Introduced by | Bruce Merrifield, 1963 (cited in Kent, 2025) |
| Typical resin support | Crosslinked copolymer of styrene and 1% meta-divinylbenzene (S-DVB), around 50 micrometre beads |
| Assembly direction | From the C-terminal amino acid towards the N-terminus to minimise racemisation |
| Common protecting chemistry | Fmoc chemistry (base-removable N-alpha group, acid-labile side-chain groups); Boc chemistry now rarer |
| Main crude by-products | Deletion sequences, truncated chains (terminations) and covalent modifications |
| Analytical verification principle | At least two high-resolution methods on separation principles distinct from purification, plus sequence confirmation (Kent, 2025) |
| Source | Kent SBH, Journal of Peptide Science, 2025;31(5):e70013 |
| Manufacturing claims for Form Laboratories products | None on this page |
| Use | Research reference material. Not for human or animal use |
What is the principle of solid-phase peptide synthesis?
Solid-phase peptide synthesis builds a peptide by forming peptide bonds one amino acid at a time while the chain remains covalently attached to an insoluble resin support. Bruce Merrifield introduced this method in 1963. The C-terminal amino acid of the target sequence is anchored to crosslinked polymer beads, most commonly a copolymer of styrene and 1% meta-divinylbenzene (S-DVB) fractionated to about 50 micrometres in diameter. Subsequent residues are added towards the N-terminus to minimise racemisation, using temporary alpha-amino protection, carboxyl activation and semi-permanent side-chain protection.
Kent notes that the near-universal adoption of SPPS rests on more than simple filtration washes, quantitative recovery of the resin-bound chain at each cycle and ease of automation. In organic solvents, S-DVB beads swell to three to five times their dry volume, and chain assembly happens inside the solvent-swollen polymer network.
Because the resin polymer and the protected peptide chains are chemically dissimilar and the polymer crosslinks prevent phase separation, resin-bound protected chains show enhanced solvation compared with protected chains in free solution. Fmoc chemistry, which removes the N-alpha fluorenylmethyloxycarbonyl group under basic conditions while keeping acid-labile side-chain protection, is now the most widely used version; Boc chemistry, based on graduated acid lability, was once dominant and is now more rarely used.
- Guidepeptide bondsA peptide bond is the amide link that joins two amino acids. How it forms, where it sits, how to count bonds, which foods contain them, and what synthetic peptides and peptide vaccines are.
What are the main limitations and by-products of stepwise SPPS?
Because stepwise SPPS does not purify the resin-bound peptide between coupling cycles, every resin-bound side reaction accumulates until the finished chain is cleaved from the support. Kent reports that in stepwise synthesis of chains containing roughly 15 or more amino acids, large numbers of low-level by-products form, and their combined amount often exceeds the amount of target peptide in the crude product. These by-products include deletion sequences (missing one or more internal residues), truncated sequences or terminations (shorter chains with free or blocked N-termini), and covalent chemical modifications.
Covalent modifications formed during chain assembly include isobaric isomerisations such as N-to-O acyl shifts and racemisation, which share the same molecular mass as the target chain, as well as mass-shifting changes such as succinimide ring formation and hydrolysis of amide side chains. Because most of these by-products closely resemble the target peptide in structure and chromatographic behaviour, purifying the crude mixture is demanding.
Kent also highlights chemical efficiency limits in conventional Fmoc SPPS. The Fmoc protecting group alone is roughly twice the average amino acid residue mass, so only about one-third of a typical Fmoc-amino acid ends up in the target chain, and a three- to five-fold excess of each protected amino acid is commonly used to drive coupling. Solvent waste during chain assembly and preparative reverse-phase HPLC purification produces high process mass intensity. For chains longer than around 35 to 40 residues, Kent recommends convergent synthesis by native chemical ligation of purified unprotected segments rather than stepwise SPPS alone.
For how synthesis-derived by-products sit alongside degradation and non-peptide impurities in regulatory categories, see the types of peptide impurities page.
Guidethe types of peptide impurities pageThe main categories of impurity in a synthetic peptide: sequence-related, degradation products and non-peptide material, and why different tests look for different categories. Cited to the EMA guideline.
What do SPPS by-products mean for quality testing?
The mix of closely related by-products left by stepwise SPPS directly shapes how a purified synthetic peptide has to be checked. Kent writes that when preparative reverse-phase HPLC is used to purify a synthetic peptide, checking the purified material only by analytical HPLC or analytical LC-MS is not meaningful as proof of homogeneity. Instead, homogeneity should be established with at least two high-resolution analytical methods that rely on distinct separation principles and differ from the method used to purify the sample.
Kent cites direct-infusion electrospray mass spectrometry, which reveals peptide components with masses different from the target, alongside capillary electrophoresis or isoelectric focusing, which separate co-products according to charge. Those orthogonal checks address impurities that can co-elute on the same reverse-phase column.
Kent also stresses that confirming the expected molecular mass by electrospray mass spectrometry is necessary, but not sufficient, to verify covalent structure. Isobaric by-products such as racemised residues or N-to-O acyl shift isomers carry the exact same mass as the intended peptide. Experimental verification of the amino acid sequence, for example by MALDI-TOF mass spectrometry ladder sequencing, is therefore part of establishing covalent identity.
Guideanalytical HPLC
Evidence limits
What does this page not show?
This page makes no claim about how any Form Laboratories product was synthesised, purified or tested, and it shows no analytical result for any batch. It is a summary of one published perspective essay on solid-phase peptide synthesis and does not provide a synthesis recipe, reagent amounts or laboratory procedure. Form Laboratories supplies research material for research use only, not for human or animal use.
Kent's 2025 essay is a perspective paper that also proposes a future green-chemistry route combining aqueous N-carboxyanhydride (NCA) SPPS, sample-displacement chromatography and native chemical ligation. The author notes that aqueous NCA SPPS remains at an early proof-of-concept stage and requires further research on NCA sensitivity to moisture and reaction optimisation.
Comparison
Key aspects of stepwise SPPS and analytical verification as summarised in Kent (Journal of Peptide Science, 2025). This table describes the published essay, not any Form Laboratories product.
| Stage | What happens in stepwise SPPS | Limitation noted in Kent (2025) | Testing implication |
|---|---|---|---|
| Chain assembly on resin | Amino acids couple one by one from C-terminus to N-terminus inside solvent-swollen S-DVB resin beads | No intermediate purification; deletions, terminations and side-chain modifications accumulate on the resin | Crude material from chains of about 15 or more residues often contains more total by-product than target peptide |
| Cleavage and purification | Side-chain protecting groups are removed, the peptide is released from the resin, and preparative reverse-phase HPLC separates the crude mix | Many by-products share closely similar structures and chromatographic properties with the target chain | Analytical reverse-phase HPLC alone repeats the purification principle and does not by itself establish homogeneity |
| Post-purification verification | Independent analytical methods check homogeneity and covalent structure | Mass confirmation alone misses isobaric isomerisations such as racemisation or N-to-O acyl shifts | Kent recommends at least two orthogonal separation methods (such as direct-infusion ESI-MS plus capillary electrophoresis or IEF) and experimental sequence verification |
FAQ
What is solid-phase peptide synthesis?
Solid-phase peptide synthesis (SPPS) is the stepwise chemical assembly of a peptide chain while its C-terminal residue stays covalently attached to an insoluble polymer resin bead. Bruce Merrifield introduced the method in 1963, and Fmoc chemistry is currently the most widely used form (Kent, 2025).
Why does SPPS produce deletion and truncated sequences?
In stepwise SPPS, the resin-bound peptide is not purified between coupling cycles. Incomplete additions leave deletion sequences missing one or more internal amino acids, while premature terminations leave shorter truncated chains with free or blocked N-termini. For chains of around 15 or more residues, Kent notes that total crude by-products often exceed the target peptide.
Why is a single HPLC check not enough after reverse-phase HPLC purification?
Kent writes that when preparative reverse-phase HPLC is used to purify a synthetic peptide, checking the product only with analytical HPLC or analytical LC-MS is not meaningful for proving homogeneity. He recommends at least two high-resolution methods based on separation principles different from purification, such as direct-infusion electrospray mass spectrometry and capillary electrophoresis or isoelectric focusing.
Does confirming molecular weight prove a synthetic peptide has the right structure?
No. Kent notes that matching the expected mass by electrospray mass spectrometry is necessary but not sufficient to verify covalent structure, because isobaric by-products such as racemised peptides or N-to-O acyl shift isomers share the same mass. Sequence confirmation is also needed.
Does this page describe how Form Laboratories products are made?
No. This page summarises published scientific literature on solid-phase peptide synthesis for research reference only. It makes no claim about how any Form Laboratories product was manufactured and gives no synthesis recipe. Form Laboratories supplies research material for research use only, not for human or animal use.
More in this hub
- GuidePeptide SciencePeptide science questions answered from published studies and regulator records: what peptides are, which are approved in Australia and by the FDA, and where research peptides sit.
- GuideIs SLU-PP-332 a peptide, and what harm record exists?SLU-PP-332 is a small molecule. Read what its chemistry record and mouse paper show, and why human side effects remain unknown.
- GuideWhat is SS-31, and did its trial measure weight loss?SS-31 is also called elamipretide. Read what its Barth syndrome trial measured, what the FDA approved, and why those findings cannot show weight loss.
- GuideWhich peptides are approved in Australia and by the FDA?Which peptide medicines the TGA and the FDA have approved, how approval differs from availability, and where research peptides sit, with records checked 14 October 2026.
- GuideWhat are peptides? Meaning, medicines, safety and legal status in AustraliaWhat peptides are: short chains of amino acids made by the body, some approved as medicines. Regulator and study evidence, safety records and Australian legal status. Research material is not a medicine.
- GuideWhat is a peptide bond? Peptide structure, chemistry and synthetic peptides explainedA peptide bond is the amide link that joins two amino acids. How it forms, where it sits, how to count bonds, which foods contain them, and what synthetic peptides and peptide vaccines are.
- GuideCitrullinated peptide antibodies: what anti-CCP is, why the test peptide is cyclic and how it is pronouncedAnti-CCP antibodies bind a lab-made cyclic peptide that contains citrulline. How citrullination works, why the test peptide is a ring, what the test measures, how the 2010 ACR/EULAR criteria use it, and how to say the name.
- GuidePeptide vs protein: what is the difference? Peptides compared with proteins, hormones, collagen and approved medicinesPeptide vs protein, hormone, steroid and collagen compared: size conventions, natural vs synthetic, research vs compounded, and what published trials and regulators record. Research material is not a medicine.
- GuideWhat do peptides do? What published studies foundWhat peptides do in the body, and what published studies found on weight, skin, growth hormone, joints and inflammation. Research material is not a medicine.
- GuidePeptide side effects: what studies and regulators have recordedAdverse events recorded for peptides in named trials, case reports, FDA and TGA documents, with study type, size and the limits of available human evidence.
- GuideDo peptides show up on drug tests? How peptides are tested and labelledWhether peptides show up on workplace and sport drug tests, how laboratories test peptide material for identity and purity, and what labelling a peptide means.
- GuideWhat have collagen peptide studies measured about muscle?What human collagen peptide studies measured about muscle protein building, body composition and strength, with the limits of each measurement explained.
- GuidePeptide solubility: what sequence, solvent, pH and aggregation doWhy some peptides dissolve and others do not: what two published studies report about sequence, solvent properties, pH and aggregation. Research reference only, with no preparation steps.
- GuidePeptide aggregation: physical association, sequence, interfaces and detectionHow peptide aggregation differs from chemical degradation, what a published review reports on sequence, surfaces, impurities and kinetics, and how aggregates are detected. Research reference only.
- GuidePeptide oxidation: chemical pathway, prone residues, triggers and detectionWhat peptide oxidation is as a chemical degradation pathway, which amino acid residues oxidise readily, what triggers oxidation, and how analytical methods detect it. Research reference only.
- GuideCell-penetrating peptides: classes, cellular entry pathways, prediction and delivery limitsWhat cell-penetrating peptides are, how cationic, amphipathic and hydrophobic classes differ, how direct translocation and endocytosis work, how sequences are predicted, and the known limits of cargo delivery. Research reference only.
- GuideThymosin alpha-1: sequence, TB-500 and published researchWhat thymosin alpha-1 is, how its sequence differs from thymosin beta-4 and TB-500, and what published immune-cell research has studied.
- GuideWhat is a signal peptide, and how does it direct a protein?What a signal peptide sequence means, how cells recognise a protein's address, and why protein targeting differs from cosmetic signal-peptide language.
- GuideWhat is carnosine, and what do studies measure?Carnosine explained: its amino acid parts, acid buffering, chemical reactions, and what enzyme tests and human muscle measurements can establish.
- GuideWhat is CGRP, and how does its signalling work?CGRP explained: the body's nerve messenger, its CLR and RAMP1 receptor, cell signals, blood-vessel studies and the limits of each kind of evidence.
- GuideWhat is icotrokinra, and what do receptor studies measure?Learn what icotrokinra is, how the IL-23 receptor works, and why binding, cell signals and human biomarkers answer different research questions.
- GuideWhat is irisin, and how is it studied?Irisin explained: its relationship to FNDC5, protein and peptide terminology, cell signalling studies, human blood measurements and the limits of the evidence.
- GuideWhat is lunasin, and what have studies measured?Lunasin is a soybean peptide studied through chemical analysis, cell experiments and human measurements. Learn what each study measured and what remains unknown.
- GuideWhat is pramlintide, and how does amylin signalling work?Pramlintide explained through amylin biology: peptide structure, receptor partners, cell signals, human study measurements and the limits of research material.
- GuideWhat is peptide YY, and what do studies measure?Peptide YY explained: the gut's natural signal, PYY forms and receptors, and what blood tests, animal experiments and human studies can show.
- GuideWhat does TAT-DATNT refer to in peptide research?The meaning of TAT-DATNT, its link to dopamine transporter research, a published sequence mismatch, and the limits of laboratory evidence.
Citations
1 sourcesKent SBH. Journal of Peptide Science. 2025;31(5):e70013.
doi:10.1002/psc.70013- Sourcedoi:10.1002/psc.70013
Continue
Research reference material: lab report shown where one is on fileMore in the peptide science hubForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
